OSLO, Norway--(BUSINESS WIRE)-- Regulatory News:
Financial calendar for 2014:
4thquarter results 2013: 20 February 2014
1stquarter results 2014: 15 May 2014
Annual General Meeting: 22 May 2014
2ndquarter results 2014: 21 August 2014
3rdquarter results 2014: 6 November 2014
About DiaGenic ASA
DiaGenic (DIAG.OL) is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com
This information was brought to you by Cision http://news.cision.com
Contact:
Paul de Potocki, Chief Executive Officer
Telephone: 47 2324 8950
e-mail: paul.depotocki@diagenic.com
or
Ruben Ekbråten, Chief Financial Officer
Telephone: 47 2324 8950
e-mail: ruben.ekbraten@diagenic.com
Help employers find you! Check out all the jobs and post your resume.
